EnteroBiotix has announced the completion of patient enrolment in the Phase IIa MAST clinical trial evaluating its investigational microbiome therapy EBX-102-02 in patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for certain blood cancers.

The study has enrolled 50 adult patients who will receive either EBX-102-02 or a matched placebo prior to conditioning chemotherapy for transplantation. Participants will be monitored for a period of 12 months following the transplant procedure to evaluate outcomes.

The MAST trial is sponsored by Imperial College London and funded by the Medical Research Council. The study is being led by Professor Julian Marchesi and Dr Jiri Pavlu in collaboration with haematologists from several leading transplant centres across the United Kingdom.

Patients undergoing allogeneic stem cell transplantation often experience significant disruption of the gut microbiome due to intensive treatments such as chemotherapy and antibiotics. This loss of microbial diversity has been linked to higher risks of infection, development of Graft-versus-Host Disease and reduced survival rates.

The trial aims to determine whether a single pre-emptive oral dose of EBX-102-02 can help restore and preserve microbial diversity in the gut during the transplantation period. The primary endpoint focuses on measuring changes in gut microbiota diversity, while secondary and exploratory endpoints include safety, tolerability, transplant outcomes and immune system responses.

MAST forms part of EnteroBiotix’s broader clinical development programme focused on microbiome-based therapies. The company has previously reported encouraging Phase IIa results in Irritable Bowel Syndrome and Phase Ib data in Liver Cirrhosis, supporting its strategy to develop microbiome therapeutics for a range of gastrointestinal and systemic diseases.

EBX-102-02 is a next-generation microbiome therapy developed using proprietary manufacturing processes designed to safely restore microbial ecosystems in the gut. The product is formulated for oral delivery and is intended to provide consistent microbial diversity with strong stability.

Topline results from the MAST trial are expected in the first half of 2027.